Pharmaceutical

Lilly partners with Haya for lncRNA obesity target deal worth $1bn

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.

Sep 6, 2024 - 04:00
Lilly partners with Haya for lncRNA obesity target deal worth $1bn
Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal.
Read the original article

Tags:

Previous Article

ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy

Next Article

Moderna mpox mRNA vaccine shows early promise in monkey study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

Novo Nordisk and NanoVation sign $600m deal in rare and...

Sep 20, 2024

STAT+: White House official dings Bristol Myers Squibb for fighting off generic competition

STAT+: White House official dings Bristol Myers Squibb ...

Nov 29, 2023

STAT+: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high

STAT+: Gilead and Teva defend antitrust claims that pri...

May 25, 2023